Buy granules india: Nirmal Bang

Granules India posted subdued sales growth of 3% yoy to Rs 363.6 cr for the quarter, due to capacity constraints in Paracetamol and Metformin however EBITDA margins improved by 100 bps on account of favorable product mix leaning towards formulations (37% of sales vs 29% in Q2FY16). 

The company posted EBITDA margins of 20.4% vs 19.4% in Q2FY16 and vs 19.6% in Q1FY17. The company is undergoing capex program (earmarked Rs 314 cr for FY17 and similar number for FY18) for increasing the capacities in addition to greenfield facility at Virginia. Increased capacities are likely to be operational by FY17 end or early FY18. 

Management has maintained revenue growth guidance of 10-15% for FY17. In last 5 years the company has shown robust growth and grew at CAGR of 24.7% with PAT CAGR of 41.5%. For the next two years we expect the company’s sales to grow by 14% and PAT by 28%, due to higher profitability in Omnichem and higher contribution by formulations business. 

We believe current year is an year of consolidation wherein it is making all possible efforts to prepare a base for future growth momentum. We have assigned a multiple of 18x FY18E earnings and based on that we recommend BUY on the stock for price target of Rs 156.